Reset
Showing 5 of 5 academic articles

Efficacy, safety, and quality of life 4 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A in the phase 3 GENEr8-1 trial

Andrew D. Leavitt, Johnny Mahlangu, Priyanka Raheja, Emily Symington et al. • Research and Practice in Thrombosis and Haemostasis (2024)

Background: Valoctocogene roxaparvovec, an adeno-associated virus-mediated gene therapy for severe hemophilia A, enables endogenous factor (F)VIII expression and provides bleed protection. Objectives: Determine valoctocogene roxaparvovec du...

DOAJ Open Access (DOAJ) DOI: 10.1016/j.rpth.2024.102615